Surgery Websites
Thoracic Oncology Program »  Meet the Team »  Thoracic Surgeons »  Johannes R. Kratz, M.D.
Johannes R. Kratz, M.D., FACS

Johannes R. Kratz, M.D., FACS

Assistant Professor of Surgery
Division of Adult Cardiothoracic Surgery
Van Auken Endowed Chair in Thoracic Oncology
Director, Minimally Invasive and Robotic Thoracic Surgery
Associate Director, Thoracic Surgery Residency Program

Contact Information

Clinic: 415-885-3882
Academic Office: 415-353-7502
Johannes.Kratz@ucsf.edu
Open Popup
  • M.D. Harvard Medical School, Boston, MA., Magna cum laude, 2006
  • M.A. Stanford University, Palo Alto, CA., Philosophy, 2000
  • B.S. Stanford University, Palo Alto, CA., Biological Sciences (with Honors with Distinction), 1999
  • B.A. Stanford University, Palo Alto, CA.,Philosophy (with Distinction), 1999
  • 6/06-6/14 Resident, Department of General Surgery. Massachusetts General Hospital, Boston, MA.
  • ACGME Fellowship in Thoracic Surgery, UCSF, 2014-2017
  • Surgical Robotics Fellowship, American Association of Thoracic Surgery Graham Foundation, Beverly, MA 2015 - 2016
  • Advanced Surgical Robotics Fellowship, University of Alabama, Birmingham (Dr. Cerfolio), 2016
  • Research Fellow, Thoracic Oncology Laboratory, University of California, San Francisco, 2008-2011
  • Research in Vascular Biology, Dr. Guillermo Garcia-Cardena, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
  • American Board of Surgery
  • American Board of Thoracic Surgery
  • Carcinoid Tumors
  • Chest Wall Tumors
  • Lung Transplantation
  • Malignant Mesothelioma
  • Mediastinal Masses
  • Minimally Invasive Thoracic Surgery
  • Non-Small Cell Lung Cancer
  • Robotic Thoracic Surgery
  • Small Cell Lung Cancer
  • Thymoma & Thymic Carcinoma
  • Tracheal Tumors
  • Video-Assisted Thoracoscopic Surgery (VATS)
  • Inflammation in lung tumorigenesis
  • Molecularly-targeted cancer therapies
  • Prognostic assays for early stage lung cancer

Johannes R. Kratz, M.D. is Director of Minimally Invasive and Robotic Thoracic Surgery and holds the Van Auken Endowed Chair in Thoracic Oncology. Kratz graduated magna cum laude from Harvard Medical School and holds a Masters in Philosophy from Stanford. 

Kratz worked as research fellow in the Thoracic Oncology Lab from 2008-2011 where he played a pivotal role in the development of a prognostic assay for early-stage lung cancer patients. The novel assay was validated in an international clinical trial led by thoracic surgeons David M. Jablons, M.D. and Michael Mann, M.D. The assay better predicted risk of death in early-stage lung cancer patients versus conventional staging guidelines and later successfully identified Stage 1A lung cancer patients who had a very high likelihood of mortality after surgery. Kratz finished his clinical training as a clinical fellow in Thoracic Surgery at UCSF from 2014 - 2017.

Kratz has published numerous papers and has been the recipient of numerous awards and honors including the Partners Healthcare Resident/Fellow as Teacher Award, Willard M. Daggett Award, Edward Churchill Surgical Research Fellowship, Wyeth Scholarship of the American College of Surgeons, John E. Thayer Scholarship Award, Howard Hughes Medical Fellows Program Continued Support Award, Howard Hughes Medical Student Research Fellowship, and designation as a Soma Weiss Scholar.

Kratz was recently honored with the 2017 UCSF Health Exceptional Physician Award for service during the last year of his clinical fellowship, among 8 winners out of 61 nominees, notably the only clinical fellow at UCSF to receive the award in 2017, and one of only two winners not on the faculty.

Personalized Therapy For Early Stage Lung Cancer At UCSF

The Kratz lab focuses on the genetic and immunological mechanisms that drive early-stage, surgically resectable thoracic malignancies. These malignancies include lung cancer, esophageal cancer, and thymic cancer. The lab uses novel high-throughput "-omics" techniques such as genomic DNA and RNA sequencing, proteomics, and metabolomics to unravel the complex nature of early-stage thoracic malignancies. At the same time, the lab actively investigates the complex immunological landscapes that nurture the growth of these malignancies. The knowledge gained from these investigations is being used to identify novel therapeutic targets and therapies for patients with early-stage, yet deadly thoracic malignancies.

Most recent publications from a total of 45
  1. Haro GJ, Sheu B, Marcus SG, Sarin A, Campbell L, Jablons DM, Kratz JR. Perioperative Lung Resection Outcomes After Implementation of a Multidisciplinary, Evidence-based Thoracic ERAS Program. Ann Surg. 2019 Dec 05. View in PubMed
  2. Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer. JAMA Netw Open. 2019 Dec 02; 2(12):e1917062. View in PubMed
  3. Greg J. Haro, Fang Yu Sheu, Stanley J. Rogers, David M. Jablons, Johannes R. Kratz. Esophagectomy Outcomes after Implementation of an Enhanced Recovery after Surgery Program. . 2019 Oct 1; 229(4):s277. View in PubMed
  4. G. Woodard, V. Ding, I. Kim, K. Jones, G. Chavez, G. Haro, J. Kratz, M. Mann, J. Rotow, C. Blakely, D. Jablons. MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC. Journal of Thoracic Oncology. 2019 Oct 1; 14(10):s271-s272. View in PubMed
  5. Greg J. Haro, Fang Yu Sheu, Stanley J. Rogers, David M. Jablons, Johannes R. Kratz. Esophagectomy Outcomes after Implementation of an Enhanced Recovery after Surgery Program. Journal of the American College of Surgeons. 2019 Oct 1; 229(4):s277. View in PubMed
  6. J. Rotow, A. Urisman, C. Mccoach, T. Jahan, T. Bivona, K. Jones, A. Gupta, H. Do, J. Riess, D. Aisner, R. Doebele, D. Jablons, J. Kratz, C. Blakely. P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2019 Oct 1; 14(10):s578. View in PubMed
  7. Jiang L, Tolani B, Yeh CC, Fan Y, Reza JA, Horvai AE, Xia E, Kratz JR, Jablons DM, Mann MJ. Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma. Cancer Manag Res. 2019; 11:8209-8218. View in PubMed
  8. Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, Gubens MA, Jahan TM, Jones KD, Kim IJ, He B, Jablons DM, Mann MJ. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging. J Thorac Oncol. 2019 Jul; 14(7):1223-1232. View in PubMed
  9. Lancaster EM, Jablons D, Kratz JR. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development. Genet Test Mol Biomarkers. 2019 Mar 22. View in PubMed
  10. Haro GJ, Seeley EJ, Jablons DM, Kratz JR. Central Airway Obstruction Due to Tracheal Glomus Tumor. Thorac Cardiovasc Surg Rep. 2018 Jan; 7(1):e43-e45. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Johannes R. Kratz, M.D., FACS
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

 

Site Directory
    X